Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01533935 · ClinicalTrials.gov registry record · Phase 3
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 291
- Enrollment target
NCT01533935 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 291 participants.
The verdict
NCT01533935, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 291 participants
- Enrollment target
Study Summary
The primary objective of this trial is to investigate the effect of 6 weeks treatment with tiotropium + olodaterol fixed dose combination inhalation solution on lung hyperinflation and exercise tolerance in patients with COPD.
Interventions
- DRUG Placebo
- DRUG Tiotropium
- DRUG Olodaterol
- DRUG Tiotropium + Olodaterol
- DRUG tiotropium + Olodaterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01533935
The ClinicalTrials.gov registry entry for NCT01533935 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01533935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01533935 about?
NCT01533935 is a clinical study titled "Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.". The primary objective of this trial is to investigate the effect of 6 weeks treatment with tiotropium + olodaterol fixed dose combination inhalation solution on lung hyperinflation and exercise tolerance in patients with COPD.
What is the current status of trial NCT01533935?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 291 participants. The study started on 2012-02. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01533935?
The interventions under investigation include: Placebo (DRUG), Tiotropium (DRUG), Olodaterol (DRUG), Tiotropium + Olodaterol (DRUG), tiotropium + Olodaterol (DRUG).
Who is sponsoring clinical trial NCT01533935?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.